Calcitonin and calcitonin receptor-like receptors:common themes with family B GPCRs?

The calcitonin receptor (CTR) and calcitonin receptor-like receptor (CLR) are two of the 15 human family B (or Secretin-like) GPCRs. CTR and CLR are of considerable biological interest as their pharmacology is moulded by interactions with receptor activity-modifying proteins. They also have therapeutic relevance for many conditions, such as osteoporosis, diabetes, obesity, lymphatic insufficiency, migraine and cardiovascular disease. In light of recent advances in understanding ligand docking and receptor activation in both the family as a whole and in CLR and CTR specifically, this review reflects how applicable general family B GPCR themes are to these two idiosyncratic receptors. We review the main functional domains of the receptors; the N-terminal extracellular domain, the juxtamembrane domain and ligand interface, the transmembrane domain and the intracellular C-terminal domain. Structural and functional findings from the CLR and CTR along with other family B GPCRs are critically appraised to gain insight into how these domains may function. The ability for CTR and CLR to interact with receptor activity-modifying proteins adds another level of sophistication to these receptor systems but means careful consideration is needed when trying to apply generic GPCR principles. This review encapsulates current thinking in the realm of family B GPCR research by highlighting both conflicting and recurring themes and how such findings relate to two unusual but important receptors, CTR and CLR.

Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes

Dipeptidyl peptidase IV (DPP IV) is a widely distributed physiological enzyme that can be found solubilized in blood, or membrane-anchored in tissues. DPP IV and related dipeptidase enzymes cleave a wide range of physiological peptides and have been associated with several disease processes including Crohn's disease, chronic liver disease, osteoporosis, multiple sclerosis, eating disorders, rheumatoid arthritis, cancer, and of direct relevance to this review, type 2 diabetes. Here, we place particular emphasis on two peptide substrates of DPP IV with insulin-releasing and antidiabetic actions namely, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). The rationale for inhibiting DPP IV activity in type 2 diabetes is that it decreases peptide cleavage and thereby enhances endogenous incretin hormone activity. A multitude of novel DPP IV inhibitor compounds have now been developed and tested. Here we examine the information available on DPP IV and related enzymes, review recent preclinical and clinical data for DPP IV inhibitors, and assess their clinical significance.

Extra-nuclear telomerase reverse transcriptase (TERT) regulates glucose transport in skeletal muscle cells

Telomerase reverse transcriptase (TERT) is a key component of the telomerase complex. By lengthening telomeres in DNA strands, TERT increases senescent cell lifespan. Mice that lack TERT age much faster and exhibit age-related conditions such as osteoporosis, diabetes and neurodegeneration. Accelerated telomere shortening in both human and animal models has been documented in conditions associated with insulin resistance, including T2DM. We investigated the role of TERT, in regulating cellular glucose utilisation by using the myoblastoma cell line C2C12, as well as primary mouse and human skeletal muscle cells. Inhibition of TERT expression or activity by using siRNA (100. nM) or specific inhibitors (100. nM) reduced basal 2-deoxyglucose uptake by ~. 50%, in all cell types, without altering insulin responsiveness. In contrast, TERT over-expression increased glucose uptake by 3.25-fold. In C2C12 cells TERT protein was mostly localised intracellularly and stimulation of cells with insulin induced translocation to the plasma membrane. Furthermore, co-immunoprecipitation experiments in C2C12 cells showed that TERT was constitutively associated with glucose transporters (GLUTs) 1, 4 and 12 via an insulin insensitive interaction that also did not require intact PI3-K and mTOR pathways. Collectively, these findings identified a novel extra-nuclear function of TERT that regulates an insulin-insensitive pathway involved in glucose uptake in human and mouse skeletal muscle cells. © 2014 Elsevier B.V.

A prototype bone screw design for osteoporotic bone

Poster. Introduction: One in five menand one half of women over the age of 50 will experience a bone fracture, whichis frequently accompanied by poor bone health. This combination of poor bonehealth and fracture is a two edge sword, because not only does poor bone healthmake fractures more likely, it also reduces the efficacy of standard fracturetreatments. Currently available surgical fixation devices that were originallydeveloped for healthy bone, such as pins, plates and bone screws, are often noteffective for patients with osteoporosis, resulting in unsatisfactory outcomesor longer and more painful recovery times. One major issue is the design ofbone screws, which can loosen or pull-out from osteoporotic bone. Osteopenicscrews with larger outer thread diameters have been developed to try andaddress this problem. The larger diameter screws have been shown to be 60–70 %stronger in lab tests of individual screws but the larger diameter screwscannot be used with the standard spacing in fixation plates without the risk ofcausing fractures between the screws. In addition, many fractures occur nearjoints where there is not room to increase the spacing between screws.Therefore, new bone screws are needed for treatment of fractures in osteoporoticbone. Materials and Methods: Afterdeveloping a novel bone screw design, we fabricated screws using rapidprototyping methods. Screws were inserted into 10 pcf density sawbones polyurethanefoam as a model for osteoporotic bone. Pull-out tests were conducted using theprototype bone screw design and the standard screw design for comparison inaccordance with ASTM 543-13. Results and Discussion: Ourprototype screws have the same outer diameter as standard bone screws, but haveoptimised threads. For pull-out tests in 10 psf density sawbones poly-urethanefoam, the prototype screw design was 60 % stronger than the standard bone screwdesign (p<0.01). Conclusion: Our novel bonescrew design provides significant improvement in standard tests with syntheticbone material. Additional tests are needed to determine if the bone screwswould be suitable for human trials.